A study led by scientists at NYU Langone Health and its Perlmutter Cancer Center has shown that monitoring blood levels of DNA fragments shed by dying tumor cells may accurately predict skin cancer ...

A new study presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC) demonstrates that monitoring circulating tumor DNA (ctDNA) can refine ...

Prognostic Indicators of Preoperative Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Efficacy in Locally Advanced Gastroesophageal and Gastric Cancer: Integrating Biomarker Analysis and ...

Induction Nivolumab Before Chemoradiation in High-Risk Human Papillomavirus–Driven Oropharynx Cancers: IMMUNEBOOST-HPV, a Multicenter Randomized Phase II Trial TF was detectable in 75.4% of baseline ...

Circulating tumor DNA (ctDNA), small pieces of DNA released from dying tumor cells into the bloodstream, can be easily and non-invasively identified and examined through a simple blood test. This ...

A blood test that detects tumor DNA circulating in the bloodstream may help select the most effective treatment options for cancer patients whose tumors have started to spread, according to one of the ...

Dr. Debu Tripathy discusses recent research on the use of circulating tumor DNA in metastatic breast cancer care. Circulating tumor DNA, also referred to as ctDNA, are small pieces of DNA that are ...

Circulating tumor DNA (ctDNA) is emerging as a promising biomarker to predict treatment response in patients with metastatic renal cell carcinoma (mRCC). In a recent study, Alan Tan, MD, of Vanderbilt ...

NeoCircle validates Pathlight MRD ctDNA detection in early breast cancer, predicting progression months to years ahead of ...

CURE editor-in-chief Dr. Joshua Sabari explores how ctDNA liquid biopsies could transform breast cancer care while balancing costs and patient anxiety. Breast cancer is common, affecting 1 in 8 women ...